CD8A and neoplasm: In addition to outperforming the other DC subset at cross-presentation, tumor cDC1s are a primary producer of IL-12 (27), which contributes to CD8+ T-cell proliferation and effector function and is associated with higher rates of responsiveness to chemotherapy (56).